Study: Nearly 1 million people in U.S. have MS

October 26, 2017
Preliminary results from a new study identified nearly 1 million people living with MS in the United States. This is more than twice the previously reported number, which was a result of a 1975 national study.
 
For some time, many experts have doubted the accuracy of the estimate of 400,000 affected by MS in the United States, since this estimate was based on scientific research done to establish the prevalence of MS before MRI was introduced as a diagnostic method and before any disease-modifying treatments were approved for use. With these advancements, it is likely that more people are being accurately diagnosed, and that people with MS are living longer. For this reason, it has for some time been considered likely that the number of individuals affected by MS may be significantly higher. 

Diseases that affect fewer people than others may be considered a lower priority for funding by government agencies and private foundations that support research and support services. These new results indicate that research and assistance programs may be severely underfunded.

The study was presented at the seventh joint ECTRIMS-ACTRIMS meeting in Paris.

MS Focus Lending Library


Books, DVDs, and CDs are available for loan, by mail across the United States.
Learn more

Study uncovers potential risks of common MS treatment


Study finds an increased risk of events such as stroke, migraine, and depression, and abnormalities in the blood with taking beta interferon for MS.
Learn more

Regulating the MS-causing properties of Th17 cells

February 19, 2019

A new study identifies a protein regulator responsible for inducing the pathogenic properties of Th17 cells, leading to multiple sclerosis. A research team from Osaka University found that the protein Satb1 triggers a shift in immune cells, causing tissue inflammation and autoimmunity. This breakthrough could lead to new treatments targeting the source of inflammation.

Interleukin 17-producing T-helper cells are a recently-identified class of immune cells that play a major role in protection against invading pathogens. Studies have shown that excessive inflammation induced by Th17 cells is actually one of the underlying causes of many inflammatory and autoimmune disorders. But what causes Th17 cells to cross the line from helpful to harmful? To answer this question, the researchers examined genome organizer protein Satb1.

Using a mouse model of MS, the researchers deleted the Satb1 gene in Th17 cells and found that the disease no longer developed in the mice. Key to this mechanism was the lack of expression of a protein called granulocyte-macrophage colony-stimulating factor by the Satb1-defective Th17 cells. GM-CSF is a pathogenic cytokine that causes localized tissue inflammation in MS. Satb1 was also found to enhance the expression of the GM-CSF gene, confirming its role in promoting inflammation.

Satb1 also blocks the expression of a protein specially designed to suppress T-cell inflammatory activity and prevent autoimmune diseases. This protein, programmed cell death protein 1, was more highly expressed in Satb1-deficient Th17 cells compared with normal Th17 cells, indicating that Satb1 normally inhibits protein expression.

Results of mouse model studies sometimes do not translate to humans and may be years away from being a marketable treatment. However, the researchers said the results suggest that manipulating Satb1 gene expression in Th17 cells could form the basis of novel treatments for various autoimmune diseases caused by Th17 cells. If they can prevent the pathogenic processes of Th17 cells, they may be able to alleviate or even eliminate disease symptoms.

The study was published in Nature Communications.
Learn more